UNITED STATES
                             Washington, D.C. 20549

                                  SCHEDULE 13D

                    Under the Securities Exchange Act of 1934

                                GEOVAX LABS, INC.
                                     (Name of Issuer)

                                     Common Stock
                                     (Title of Securities)

                                     (CUSIP Number)

                                     Kevin Friedmann, Esq.
                                     Richardson & Patel LLP
                                     10900 Wilshire Boulevard, Suite 500
                                     Los Angeles, CA 90024
           (Name, Address and Telephone Number of Person Authorized to
                       Receive Notices and Communications)

                                     September 28, 2006
             (Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss.240.13D-1(e), 240.12d-1(f) or 240.13d-1(g), check the
following box. [ ]

Note: Schedules filed in paper format shall include a signed original and five
copies of this schedule, including all exhibits. See ss.240.13d-7 for other
parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the

CUSIP No.  373678101
1.     Names of Reporting Persons
       IRS Identification Nos. of Above Persons (Entities Only)
       Emory University
2.     Check the Appropriate Box if a Member of a Group (See Instructions)

       (a)  [ ]

       (b)  [X}

3.     SEC Use Only

4.     Source of Funds (See Instructions)  OO
5.     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items
       2(d) or 2(e)  [ ]
6.     Citizenship or Place of Organization     United States (State of Georgia)
Number of Shares Beneficially Owned by Each Reporting Person With:

7.     Sole Voting Power     233,905,253

8.     Shared Voting Power     Not Applicable

9.     Sole Dispositive Power     233,905,253

10.    Shared Dispositive Power     Not Applicable
11.    Aggregate Amount Beneficially Owned by Each Reporting Person  233,905,253
12.    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See
       Instructions)  [ ]
13.    Percent of Class Represented by Amount in Row (11)     33.02%
14.    Type of Reporting Person (See Instructions)    00

Item 1.   Security and Issuer

          Common stock, $0.001 par value, of GeoVax Labs, Inc. (the "Issuer").
The Issuer's address is 1256 Briarcliff Road N.E., Emtech Bio Suite 500,
Atlanta, Georgia 30306.

Item 2.   Identity and Background

          (a) This statement is filed by Emory University (the "Reporting

          (b) The Reporting Person's business address is Administration Building
101, 201 Dowman Drive, Atlanta, Georgia 30322.

          (c) The Reporting Person is a private, non-profit educational
institution organized under the laws of the State of Georgia.

          (d) During the last five years, the Reporting Person has not been
convicted in a criminal proceeding.

          (e) During the last five years, the Reporting Person has not been a
party to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, federal or state securities laws or finding any
violation with respect to such laws.

Item 3.   Source and Amount of Funds or Other Consideration

          This report concerns the issuance of a total of 233,905,253 shares of
the Issuer's common stock. These shares were issued in connection with a merger
that took place on September 28, 2006 by and between Dauphin Technology, Inc.,
GeoVax, Inc. and GeoVax Acquisition Corp. Upon completion of the merger, Dauphin
Technology, Inc. (now GeoVax Labs, Inc.) issued shares of its common stock,
$0.001 par value, to the shareholders of GeoVax, Inc. in exchange for their
issued and outstanding shares of GeoVax, Inc. common stock. Prior to the merger,
the Reporting Person was a holder of 7,888,320 shares of GeoVax, Inc. common
stock (or securities convertible into GeoVax, Inc. common stock). The securities
in GeoVax, Inc. were issued to the Reporting Person in exchange for the license
of certain technology owned by the Reporting Person and for cash in the amount
of $750,071.28, which were the personal funds of the Reporting Person.

Item 4.   Purpose of Transaction

          The purpose of this transaction was to effectuate the merger between
Dauphin Technology, Inc. and GeoVax, Inc.

          The acquisition of the shares described herein was done solely in
conjunction with the merger. As of the date of this report, the Reporting Person
does not have any plan or proposal

      (i) to acquire additional securities of the Issuer or to dispose of
securities of the Issuer, although it may do either of these in the future;

      (ii) that would result in an extraordinary corporate transaction, such as
a merger, reorganization or liquidation, involving the Issuer;

      (iii) that would result in the sale or transfer of a material amount of
assets of the Issuer;

      (iv) to change the composition of the Issuer's board of directors or
management, including any plans or proposals to change the number or term of
directors or to fill any existing vacancies on the board;

      (v) that would result in any material change in the present capitalization
or dividend policy of the Issuer;

      (vi) that would result in any change in the Issuer's charter, bylaws or
instruments corresponding thereto in order to impede the acquisition of control
of the Issuer;

      (vii) that would cause a class of securities of the Issuer to be delisted
from a national securities exchange or to cease to be authorized to be quoted in
an inter-dealer quotation system of a registered national securities

      (viii) that would cause a class of equity securities of the Issuer
becoming eligible for termination of registration pursuant to Section 12(g)(4)
of the Act; or

      (ix) that would result in any action similar to those enumerated above.

         There are currently two employees of the Reporting Person serving on
the Issuer's Board of Directors. The Reporting Person is a private, non-profit
educational institution and the directors who are employees of the Reporting
Person intend to resign when suitable replacements to the Board have been

Item 5.   Interest in Securities of the Issuer

         The Reporting Person beneficially owns a total of 233,905,253 shares,
or approximately 33.02%, of the Issuer's common stock. The Reporting Person has
the sole power to vote and to dispose of the shares it beneficially owns. The
Reporting Person did not effect any transactions in the Issuer's common stock
during the past 60 days, other than the exchange of GeoVax, Inc. common stock
for the Issuer's common stock, which exchange was done in conjunction with the
merger. No other person has the right to receive or the power to direct the
receipt of dividends from, or the proceeds from the sale of the Reporting
Person's common stock. The name of the person who has voting or investment
control over the securities owned by the Reporting Person is Mary Cahill.

Item 6.   Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer

          Not applicable.

Item 7.   Material to Be Filed as Exhibits



          After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and

October 10, 2006

                                     Emory University

                                     By:/s/ Kent B. Alexander
                                        Kent B. Alexander, Senior Vice
                                        President and General Counsel